By Ryan DevereauxVice News.com – A viral drug test drug test company, Gilead, has been hit with a lawsuit from the FDA accusing it of “negligent marketing and deception” of a potentially life-saving drug that can prevent severe side effects of malaria drugs, including fever, joint pain, and blindness.
The lawsuit, filed on Thursday in Federal District Court in the Southern District of New York, alleges that Gileade is falsely advertising that its flu vaccine prevents a life-threatening type of malaria and, if it is administered within 48 hours, that it has no side effects.
The FDA claims that Gilade’s product was not approved for use in the United States and is not marketed in the U.S.
Gilead did not immediately respond to requests for comment.
Gilade has not been licensed for use as a malaria drug since 2004.
It was approved by the FDA in 2006 for use against malaria in the treatment of patients who have been treated with malaria drugs previously.
But the FDA later rejected its application to market it as a “non-drug malaria therapy.”
“The company’s claim that it is only licensed to market a product that has not yet been approved for clinical use is false,” the suit says.
The drug test website, which has more than 500,000 users, has a list of symptoms, such as dizziness, headache, muscle aches, and fatigue.
Users who are given the drug must fill out a questionnaire, which Gileady’s representatives claim is confidential.
The company has been accused of selling the drug as if it were a life preserver, even though Gileades website says it is not a life preserving drug.
The suit also claims that the company “fraudulently” inflated its sales and profit estimates for the vaccine, and falsely stated that its vaccine had a 70% survival rate compared to a 90% survival average for the two other malaria drugs.
Giles trial was the first to be approved for sale in the West since a similar one was approved for malaria in Europe in 2009.